Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma

Table 1 Baseline and clinical characteristics of patients

Characteristics	Number (n)	Percentage (%)	Characteristics	Number (n)	Percentage (%)
Age, yr			Sex
Mean	59.8 ± 8.08		Male	16	0.67
Range	37.1-66.2		Female	8	0.33
T stage			N stage
1	1	0.042	1	5	0.208
2	9	0.375	2	17	0.708
3	4	0.167	3	2	0.083
4	10	0.417	Differentiation
Smoking history			High	1	0.042
Nonsmoker	7	0.292	Moderately	3	0.125
20-30 yr	11	0.458	Low	12	0.5
30-39 yr	1	0.042	Uncertain	8	0.333
> 40 yr	5	0.208	Primary tumor site
History of alcohol use			Nasopharynx	9	0.375
Nondrinker	3	0.125	Larynx	5	0.208
Infrequent (< once/wk)	8	0.333	Hypopharynx	3	0.125
Light (< 3 times/wk)	2	0.083	Oral Cavity	2	0.083
Moderate (> 3 times/wk but < once/d)	6	0.25	Tongue	2	0.083
Heavy (> once/d)	5	0.208	Esophagus	2	0.083
Disease situation			Nasal cavity	1	0.042
Recurrence	10	0.417	AJCC stage
Local advancement	14	0.583	III	8	0.333
ECOG PS			IVA	13	0.542
0	0	0	IVB	3	0.125
1	22	0.917	Pre-treatment
2	2	0.083	Surgery	10	0.417
			Radiotherapy	20	0.167
			Chemotherapy	5	0.208

ECOG PS: Eastern cooperative oncology group performance status; AJCC: American joint committee on cancer.